Phase 3 Recruiting Academic/Other
This phase III trial compares stereotactic body radiation therapy (SBRT), (five treatments over two weeks using a higher dose per treatment) to usual radiation therapy (20 to 45 treatments over 4 to 9 weeks) for the treatment of high-risk …
Sponsor: NRG Oncology
NCT ID: NCT05946213
Sites in Utah: - American Fork Hospital / Huntsman Intermountain Cancer Center — American Fork, Utah
- Sandra L Maxwell Cancer Center — Cedar City, Utah
- Farmington Health Center — Farmington, Utah
- Logan Regional Hospital — Logan, Utah
- Intermountain Medical Center — Murray, Utah
Phase 3 Recruiting Industry
The purpose of this study is to evaluate the overall survival (length of time from the start of study to date of death from any cause) for pasritamig (JNJ-78278343) in combination with best supportive care (BSC) as compared to placebo with…
Sponsor: Janssen Research & Development, LLC
NCT ID: NCT07164443
Sites in Utah: - Utah Cancer Specialists — Salt Lake City, Utah
Phase 2, Phase 3 Recruiting Industry
This is a Phase II/III study. Patient population is adult participants with PSMA-positive mCRPC who had treatments with androgen receptor pathway inhibitor (ARPI) and taxane-based chemotherapy and progressed on or after \[177Lu\]Lu-PSMA ta…
Sponsor: Novartis Pharmaceuticals
NCT ID: NCT06780670
Sites in Utah: - Utah Intermountain Medical Center — Murray, Utah
Phase 3 Recruiting Industry
The intention of the study is to demonstrate superiority of AZD2265 relative to standard of care treatments by assessment of radiographic progression-free survival (rPFS) and overall survival (OS) in participants with mCRPC.
Sponsor: AstraZeneca
NCT ID: NCT07611110
Sites in Utah: - Research Site — Salt Lake City, Utah
Phase 3 Recruiting Industry
The purpose of this study is to evaluate the efficacy and safety of 177Lu-TLX591 in patients with metastatic castration-resistant prostate cancer who have progressed following treatment with Androgen Receptor Pathway Inhibitor Treatment
Sponsor: Telix Pharmaceuticals (Innovations) Pty Limited
NCT ID: NCT06520345
Sites in Utah: - Intermountain Health — Murray, Utah
- Intermountain Health — Salt Lake City, Utah
Phase 3 Recruiting Academic/Other
The goal of this clinical trial is to test the use of creatine monohydrate supplementation with resistance training to preserve muscle mass and help lessen prostate cancer progression. The main question it aims to answer is if this treatme…
Sponsor: University of Utah
NCT ID: NCT06112990
Sites in Utah: - Huntsman Cancer Institute — Salt Lake City, Utah
Phase 2 Recruiting Industry
The primary purpose of this study is to evaluate the safety, tolerability, and efficacy of SYNC-T Therapy SV-102 and to identify the maximum tolerated dose (MTD) and/or selected dose for phase 2b study.
Sponsor: Syncromune, Inc.
NCT ID: NCT06533644
Sites in Utah: - Summit Urology — Murray, Utah
Phase 2 Recruiting Industry
This Phase 2, open-label, multicenter study is conducted in patients with castration-resistant prostate cancer. Patients in this study receive MRT-2359, an investigational oral medicine, in combination with apalutamide, an oral medicine us…
Sponsor: Monte Rosa Therapeutics, Inc
NCT ID: NCT07745361
Sites in Utah: - START Mountain Region — West Valley City, Utah
Phase 1, Phase 2 Recruiting Industry
The purpose of the study is to evaluate the safety, tolerability, and efficacy of the two different treatment combinations of tulmimetostat in participants with de novo or recurrent Metastatic Hormone-Sensitive Prostate Cancer (mHSPC).
Sponsor: Novartis Pharmaceuticals
NCT ID: NCT07190300
Sites in Utah: - Huntsman Cancer Institute — Salt Lake City, Utah
Phase 1, Phase 2 Recruiting Industry
ANDROMEDA is a first-in-human, Phase I/II, open-label, multicenter study of AZD9750 in participants with metastatic prostate cancer. The trial evaluates safety, tolerability, pharmacokinetics/pharmacodynamics, and preliminary efficacy of A…
Sponsor: AstraZeneca
NCT ID: NCT07336446
Sites in Utah: - Research Site — Salt Lake City, Utah
Phase 2 Recruiting Academic/Other
This is an open-label, multi-site study of apalutamide with carotuximab in patients who have progressed on androgen receptor signaling inhibitor (ARSI) therapy. This study will begin with a safety assessment in the first 10 subjects (part …
Sponsor: Edwin Posadas, MD
NCT ID: NCT05534646
Sites in Utah: - Huntsman Cancer Institute and Hospital — Salt Lake City, Utah
Phase 1 Recruiting Industry
IDE574 is a synthetically manufactured small molecule inhibitor that co-targets the lysine acetyltransferase enzymes KAT6 and KAT7. The purpose of this study is to evaluate the safety, preliminary efficacy, pharmacokinetics (PK), and pharm…
Sponsor: IDEAYA Biosciences
NCT ID: NCT07540572
Sites in Utah: - START Mountain Region, LLC — West Valley City, Utah
Phase 1 Recruiting Industry
The study is designed to understand the safety, tolerability, pharmacokinetics, immunogenicity, and preliminary antitumor activity of MGC026 in participants with relapsed or refractory, unresectable, locally advanced or metastatic solid tu…
Sponsor: MacroGenics
NCT ID: NCT06242470
Sites in Utah: - START Mountain Region — West Valley City, Utah
Phase 1 Recruiting Industry
The primary purpose of this study is to determine the safety, tolerability, and maximum tolerated dose (MTD) of EXS74539 (REC-4539) in participants with select solid tumors.
Sponsor: Exscientia AI Ltd., a wholly owned subsidiary of Recursion Pharmaceuticals, Inc.
NCT ID: NCT07517198
Sites in Utah: - START Mountain Region — West Valley City, Utah
Recruiting Industry
International registry for cancer patients evaluating the feasibility and clinical utility of an Artificial Intelligence-based precision oncology clinical trial matching tool, powered by a virtual tumor boards (VTB) program, and its clinic…
Sponsor: Massive Bio, Inc.
NCT ID: NCT03452774
Sites in Utah: - Massive Bio SYNERGY-AI site — Salt Lake City, Utah
NA Recruiting Academic/Other
Prostate cancer has a significant impact on patient quality of life (QoL) directly, as well as through the management of localized disease (such as surgery and radiation-related incontinence, erectile dysfunction, and bowel dysfunction), a…
Sponsor: University of Utah
NCT ID: NCT07093177
Sites in Utah: - Huntsman Cancer Institute at University of Utah — Salt Lake City, Utah